Aldeyra Therapeutics EBIT

Aldeyra Therapeutics (ALDX) currently reports a EBIT of $-17T as of June 2026. That compares with $-10T in the prior-year period — down 71.1% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Aldeyra Therapeutics's EBIT history and peer comparisons.

Aldeyra Therapeutics's EBIT decreased from $-10T to $-17T — a 71.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aldeyra Therapeutics's EBIT of $-17T is lower than the Healthcare sector average of $110B. That is roughly 16293.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Aldeyra Therapeutics reported $-17T in EBIT as of June 2026. That compares with $-10T in the prior-year period — down 71.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-17T, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Aldeyra Therapeutics, and consider following ALDX for alerts when major investors trade the stock.